Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic HTN. Recent literature, however, suggests increased mortality in older patients who are exposed to larger quantities of vasopressor medications. In this podcast, we do a deep dive into the recently published 65 Trial, which sought to evaluate the effect of permissive hypotension in older patients with vasodilatory hypotension.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
As we gain more experience managing critically ill patients with COVID-19 infection there has been a shift away from immediate intubation and towards more...
This month Mike McCurdy rejoins the podcast to discuss the ATHOS-3 trial. Mike was one of the co-authors on this impressive publication and gives...
In a recent podcast we reviewed the ARREST Trial, which demonstrated significant improvement in survival among OHCA patients at a single center randomized to...
